Ajanta Pharma (AJANTPHARM) — Board Meeting

📢 Key Event
47th AGM approved FY2025-26 financials and reappointed Chairman

💡 Investor Takeaway
Shareholders endorsed key governance and financial items, maintaining confidence in leadership and reporting transparency.

Ajanta Pharma held its 47th Annual General Meeting on 16 July 2026 via video conference, where shareholders approved the consolidated financial statements for FY2025-26, confirmed the interim dividend as final, reappointed Chairman Mannalal Agrawal, and ratified cost auditor remuneration. Remote e-voting was conducted through NSDL with scrutiny by Pramod S. Shah & Associates, results to be disclosed within two working days.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AJANTPHARM ✨ Ask AI About This

About Ajanta Pharma Limited (AJANTPHARM)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹39,694.55 Cr P/E: 37.6 ROE: 23.3% ROCE: 29.4%

View full AJANTPHARM stock details →

📡 Get AI alerts when AJANTPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AJANTPHARM — Free

💡 Ask AI about this filing

"How did voting results break down by shareholder type?" "What was the exact remuneration approved for cost auditors?" "When will the audited financial statements be publicly available?"

Ask AI Free →

📊 More AJANTPHARM filings

See all AJANTPHARM filings →

🔥 Also filed on 16 July 2026

VALUEIND Value Industries Limited Announcement ARFIN Arfin India Limited Insider Trading KTKBANK The Karnataka Bank Limited Corporate Action GREENPLY Greenply Industries Limited Corporate Action LTM LTM Limited Financial Results SIGIND Signet Industries Limited Announcement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AJANTPHARM files new disclosures

Track AJANTPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.